Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trimeris has been able to boast of impressive sales results for its Roche co-developed HIV drug Fuzeon, with Q2 2006 global net sales exceeding $57 million.
Subscribe to our email newsletter
Net sales of Fuzeon in the US and Canada for the second quarter of 2006 were $31.1 million, an increase of 23% over Q2 2005. Total worldwide net sales for the quarter were $57.2 million, an increase of 6% over Q2 2005.
Brazil (a major market that purchases Fuzeon intermittently and in bulk) did not make a Fuzeon purchase in Q2 2006 as it did in Q2 2005. Excluding Brazil, worldwide net sales grew by 23%, and net sales outside the US and Canada grew by 22% over the same period last year.
“We are pleased with having achieved the second best Fuzeon sales quarter ever, particularly in the US and Canada where Fuzeon again recorded strong double digit sales growth,” said Steven Skolsky, CEO of Trimeris. “When combined with other active drugs, Fuzeon has demonstrated unprecedented antiviral activity and the availability of newer agents, such as the recently launched Prezista will be a key driver of future growth.”